Study Shows UC-II® Ability in Reducing Osteoarthritic Pain

October 6, 2008

Results of a new clinical study on UC-II®, InterHealth Nutraceuticals' (Santa Rosa, CA) Type II collagen product were presented at the American College of Nutrition (Clearwater, FL) on October 3.

Results of a new clinical study on UC-II®, InterHealth Nutraceuticals' (Santa Rosa, CA) Type II collagen product were presented at the American College of Nutrition (Clearwater, FL) on October 3.

The study tested an older arthritic population experiencing joint pain from osteoarthritis. In a sample size of 52 American patients, one group took 40mg UC-II®, and the other, a combination of glucosamine (1500mg)+ chondroitin (1200mg). Both treatments reduced their WOMAC index score, which measures stiffness, difficulty in physical function, and pain in the knee. With UC-II®, however, the WOMAC score decreased by 33% compared to 14% in glucosamine plus chondroitin-treated groups after 90 days.

"This research shows the power of InterHealth's UC-II® product," stated InterHealth CEO Paul Dijkstra. " What is most significant is that UC-II® shows better efficacy with a smaller, once daily, 40mg dose than the larger 2700mg dose of the glucosamine + chondroitin combination...Our hope is that major supplement companies will want to bring this ingredient to their consumers and promote its effectiveness over glucosamine and chondroitin in joint health."

The study was conducted at KGK Synergize Inc. (Ontario, Canada) with funding from InterHealth Nutraceuticals Inc.

Related Content:

Joint & Bone Health